Denali Therapeutics Inc. DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, ...
22h
Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 ...
Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...
Sanofi SNY announced that the phase III IRAKLIA study, which evaluated a fixed-dose subcutaneous (SC) formulation of its ...
The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the ...
Azafaros B.V. today announced that its lead asset, nizubaglustat, has been granted orphan drug designation from regulatory ...
Patients with presbyopia experienced improvements in near vision after treatment with Brimochol PF in a second phase 3 ...
The FDA’s breakthrough therapy designation for GSK’227 underscores its potential to address the critical unmet needs of ...
Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the ...
The FDA has approved Steqeyma® (ustekinumab-stba), a biosimilar to Stelara®, for the treatment of various chronic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback